# Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/doubling-epirubicin-dose-intensity-100-mg-m2-versus-50-mg-m2-in-the-fec-regimen/

## Facts

| Field | Value |
| --- | --- |
| Author Names | G Brufman,E Colajori,N. Ghilezan,M. Lassus,Monica Martoni,Н И Переводчикова,C. Tosello,Donatella Viaro,C. Zielinski |
| Citations | 79 |
| DOI | 10.1023/a:1008295427877 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://doi.org/10.1023/a:1008295427877 |
| OpenAlex ID | https://openalex.org/W2340435826 |
| PMID | 9093724 |
| Type | article |
| Year | 1997 |

## Paper authors

- [Monica Martoni](https://scholariq.org/researchers/monica-martoni/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Paper topics

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Chemotherapy-induced cardiotoxicity and mitigation](https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.